Abdominal-pelvic lymphoproliferative disease after lung transplantation: Presentation and outcome

Transplantation

Volumn 77, Issue 3, 2004, Pages 431-437

  Hachem, Ramsey R ^a   Chakinala, Murali M ^a   Yusen, Roger D ^a   Lynch, John P ^a   Aloush, Aviva A ^a   Patterson, G Alexander ^a   Trulock, Elbert P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; GANCICLOVIR; LYMPHOCYTE ANTIBODY; PREDNISOLONE; THYMOCYTE ANTIBODY;

ABDOMINAL DISEASE; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; NONHODGKIN LYMPHOMA; NONHUMAN; OUTCOMES RESEARCH; PELVIC DISEASE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SERODIAGNOSIS; TIME SERIES ANALYSIS;

ABDOMEN; BURKITT LYMPHOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; LYMPHOMA, NON-HODGKIN; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PELVIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 1142286297     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000112938.88948.F5     Document Type: Article

References (26)

1. Swerdlow SH. Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Semin Diagn Pathol 1997; 14(1): 2-7.
2. Schaar CG, Van Der Pijl JW, Van Hoek B, et al. Successful outcome with a "quintuple approach" of posttransplant lymphoproliferative disorder. Transplantation 2001; 71(1)): 47-52.
3. Hoshida Y, Li T, Dong Z, et al. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer 2001; 91: 869-875.
4. Montone KT, Litzky LA, Wurster A, et al. Analysis of Epstein-Barr virus associated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery 1996; 119: 544-551.
5. Gerstenkorn C, Jackson G, Di Franco F, et al. Outcome of PTLD in renal and liver allograft recipients. Transplant Proc 2001; 33: 2469-2472.
6. Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998; 16: 2052-2059.
7. Nelson B, Nalesnik M, Bahler DW, et al. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000; 24(3): 375-385.
8. Dotti G, Fiocchi R, Motta T, et al. Epstein-Barr virus-negative lymphoproliferative disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 2000; 69(5): 827-833.
9. Nalesnik MA, Locker J, Jaffe R, et al. Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients. Clin Transplant 1992; 6: 249-252.
10. Opelz G, Schwarz V, Wujciak T, et al. Analysis of non-Hodgkin's lymphomas in organ transplant recipients. Transplant Rev 1995; 9: 231-240.
11. Paranjothi S, Yusen R, Kraus M, et al. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. J Heart Lung Transplant 2001; 20: 1054-1063.
12. Levine SM, Angel L, Anzueto A, et al. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients. Chest 1999; 116: 1273-1277.
13. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients; ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10: 877-887.
14. Aris RM, Maia DM, Neuringer IP, et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient. Am J Respir Crit Care Med 1996; 154: 1712-1717.
15. Cooper JD, Billingham M, Egan T, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant 1993; 12: 713-716.
16. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310.
17. Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985; 152(5): 876-885.
18. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346-1353.
19. Haque T, Thomas JA, Falk KI, et al. Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol 1996; 77: 1169-1172.
20. Wigle DA, Chaparro C, Humar A, et al. Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation 2001; 72(11): 1783-1786.
21. Shahinian VB, Murihead N, Jevnikar AM, et al. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoproliferative disorder in adult renal allograft recipients. Transplantation 2003; 75(6): 851-856.
22. Manez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176: 1462-1467.
23. Mattila PS, Aalto SM, Heikkila L, et al. Malignancies after heart transplantation: presence of Epstein-Barr virus and cytomegalovirus. Clin Transplant 2001; 15: 337-342.
24. Manez R, Breinig MK, Linden P, et al. Factors associated with the development of post-transplantation lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients. Transpl Int 1994; 7(suppl 1): S235-S237.
25. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997; 14(1): 8-14.
26. Valantine HA, Berry GF. Lymphoproliferative disorders and other complications after heart transplantation. In: Baumgartner WA, Reitz B, Kasper E, et al, eds. Heart and lung transplantation. Philadelphia, WB Saunders Company 2002, pp 372-385.